Boussard & Gavaudan Investment Management LLP Halozyme Therapeutics, Inc. Transaction History

Boussard & Gavaudan Investment Management LLP

$407 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $800,807 - $967,074	21,964 New	21,964 $839,000
Q1 2023 May 11, 2023	BUY	$32.86 - $55.7 $425,734 - $721,649	12,956 New	12,956 $494,000

Others Institutions Holding HALO

# of Institutions

536

Shares Held

123M

Call Options Held

294K

Put Options Held

169K

Black Rock Inc. New York, NY

17.6M
Shares

$1.01 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$736 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$379 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$232 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$195 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.95B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boussard & Gavaudan Investment Management LLP, based on Form 13F filings with the SEC.

News

Stay updated on Boussard & Gavaudan Investment Management LLP with notifications on news.

Account